Feigin VL, Nichols E, Alam T, Bannick MS, Beghi E, Blake N, et al. Global, regional, and national burden of neurological disorders, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol. 2019;18(5):459–80.

Article  Google Scholar 

Budd Haeberlein S, Aisen PS, Barkhof F, Chalkias S, Chen T, Cohen S, et al. Two randomized phase 3 studies of aducanumab in early Alzheimer’s disease. J Prev Alzheimers Dis. 2022;9(2):197–210.

CAS  PubMed  Google Scholar 

Swanson CJ, Zhang Y, Dhadda S, Wang J, Kaplow J, Lai RYK, et al. A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer’s disease with lecanemab, an anti-Aβ protofibril antibody. Alzheimer’s Res Ther. 2021;13(1):80.

Article  CAS  Google Scholar 

van Dyck CH, Swanson CJ, Aisen P, Bateman RJ, Chen C, Gee M, et al. Lecanemab in early Alzheimer’s disease. N Engl J Med. 2023;388(1):9–21.

Article  PubMed  Google Scholar 

Mintun MA, Lo AC, Duggan Evans C, Wessels AM, Ardayfio PA, Andersen SW, et al. Donanemab in early Alzheimer’s disease. N Engl J Med. 2021;384(18):1691–704.

Article  CAS  PubMed  Google Scholar 

Sperling RA, Jack CR, Black SE, Frosch MP, Greenberg SM, Hyman BT, et al. Amyloid-related imaging abnormalities in amyloid-modifying therapeutic trials: recommendations from the Alzheimer’s Association Research Roundtable Workgroup. Alzheimer’s Dementia. 2011;7(4):367–85.

Article  Google Scholar 

Cummings J, Rabinovici GD, Atri A, Aisen P, Apostolova LG, Hendrix S, et al. Aducanumab: appropriate use recommendations update. J Prev Alzheimers Dis. 2022;9(2):221–30.

CAS  PubMed  PubMed Central  Google Scholar 

Cummings J, Apostolova L, Rabinovici GD, Atri A, Aisen P, Greenberg S, et al. Lecanemab: appropriate use recommendations. J Prev Alzheimers Dis. 2023;10(3):362–77. https://doi.org/10.14283/jpad.2023.30.

Article  CAS  PubMed  Google Scholar 

Arndt JW, Qian F, Smith BA, Quan C, Kilambi KP, Bush MW, et al. Structural and kinetic basis for the selectivity of aducanumab for aggregated forms of amyloid-β. Sci Rep. 2018;8(1):6412.

Article  PubMed  PubMed Central  Google Scholar 

Söderberg L, Johannesson M, Nygren P, Laudon H, Eriksson F, Osswald G, et al. Lecanemab, aducanumab, and gantenerumab—binding profiles to different forms of amyloid-beta might explain efficacy and side effects in clinical trials for Alzheimer’s disease. Neurotherapeutics. 2023;20(1):195–206.

Article  PubMed  Google Scholar 

Haddad HW, Malone GW, Comardelle NJ, Degueure AE, Kaye AM, Kaye AD. Aducanumab, a novel anti-amyloid monoclonal antibody, for the treatment of Alzheimer’s disease: a comprehensive review. Health Psychol Res. 2022;10(1):31925.

Article  PubMed  PubMed Central  Google Scholar 

Schenk D, Barbour R, Dunn W, Gordon G, Grajeda H, Guido T, et al. Immunization with amyloid-β attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature. 1999;400(6740):173.

Article  CAS  PubMed  Google Scholar 

Morgan D, Diamond DM, Gottschall PE, Ugen KE, Dickey C, Hardy J, et al. A beta peptide vaccination prevents memory loss in an animal model of Alzheimer’s disease. Nature. 2000;408(6815):982–5.

Article  CAS  PubMed  Google Scholar 

Gilman S, Koller M, Black RS, Jenkins L, Griffith SG, Fox NC, et al. Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial. Neurology. 2005;64(9):1553–62.

Article  CAS  PubMed  Google Scholar 

Orgogozo JM, Gilman S, Dartigues JF, Laurent B, Puel M, Kirby LC, et al. Subacute meningoencephalitis in a subset of patients with AD after Abeta42 immunization. Neurology. 2003;61(1):46–54.

Article  CAS  PubMed  Google Scholar 

Nicoll JAR, Barton E, Boche D, Neal JW, Ferrer I, Thompson P, et al. Abeta species removal after abeta42 immunization. J Neuropathol Exp Neurol. 2006;65(11):1040–8.

Article  CAS  PubMed  Google Scholar 

Holmes C, Boche D, Wilkinson D, Yadegarfar G, Hopkins V, Bayer A, et al. Long-term effects of Abeta42 immunisation in Alzheimer’s disease: follow-up of a randomised, placebo-controlled phase I trial. Lancet. 2008;372(9634):216–23.

Article  CAS  PubMed  Google Scholar 

Salloway S, Sperling R, Gilman S, Fox NC, Blennow K, Raskind M, et al. A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease. Neurology. 2009;73(24):2061–70.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Vandenberghe R, Rinne JO, Boada M, Katayama S, Scheltens P, Vellas B, et al. Bapineuzumab for mild to moderate Alzheimer’s disease in two global, randomized, phase 3 trials. Alzheimers Res Ther. 2016;8(1):18.

Article  PubMed  PubMed Central  Google Scholar 

Salloway S, Sperling R, Fox NC, Blennow K, Klunk W, Raskind M, et al. Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer’s disease. N Engl J Med. 2014;370(4):322–33.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Rinne JO, Brooks DJ, Rossor MN, Fox NC, Bullock R, Klunk WE, et al. 11C-PiB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimer’s disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study. Lancet Neurol. 2010;9(4):363–72.

Article  CAS  PubMed  Google Scholar 

Doody RS, Thomas RG, Farlow M, Iwatsubo T, Vellas B, Joffe S, et al. Phase 3 trials of solanezumab for mild-to-moderate Alzheimer’s disease. N Engl J Med. 2014;370(4):311–21.

Article  CAS  PubMed  Google Scholar 

Zhang Y, Lee DHS. Sink hypothesis and therapeutic strategies for attenuating Abeta levels. Neuroscientist. 2011;17(2):163–73.

Article  CAS  PubMed  Google Scholar 

Honig LS, Vellas B, Woodward M, Boada M, Bullock R, Borrie M, et al. Trial of solanezumab for mild dementia due to Alzheimer’s disease. N Engl J Med. 2018;378(4):321–30.

Article  CAS  PubMed  Google Scholar 

Cummings JL, Cohen S, van Dyck CH, Brody M, Curtis C, Cho W, et al. ABBY: a phase 2 randomized trial of crenezumab in mild to moderate Alzheimer disease. Neurology. 2018;90(21):e1889–97.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Salloway S, Honigberg LA, Cho W, Ward M, Friesenhahn M, Brunstein F, et al. Amyloid positron emission tomography and cerebrospinal fluid results from a crenezumab anti-amyloid-beta antibody double-blind, placebo-controlled, randomized phase II study in mild-to-moderate Alzheimer’s disease (BLAZE). Alzheimers Res Ther. 2018;10(1):96.

Article  PubMed  PubMed Central  Google Scholar 

Ostrowitzki S, Bittner T, Sink KM, Mackey H, Rabe C, Honig LS, et al. Evaluating the safety and efficacy of crenezumab vs placebo in adults with early Alzheimer disease: two phase 3 randomized placebo-controlled trials. JAMA Neurol. 2022;79(11):1113–21.

Article  PubMed  PubMed Central  Google Scholar 

Ostrowitzki S, Lasser RA, Dorflinger E, Scheltens P, Barkhof F, Nikolcheva T, et al. A phase III randomized trial of gantenerumab in prodromal Alzheimer’s disease. Alzheimers Res Ther. 2017;9(1):95.

Article  PubMed  PubMed Central  Google Scholar 

FDA Office of the Commissioner. FDA. FDA; 2023 [cited 31 May 2023]. FDA Grants Accelerated Approval for Alzheimer’s Disease Treatment. https://www.fda.gov/news-events/press-announcements/fda-grants-accelerated-approval-alzheimers-disease-treatment

Sevigny J, Chiao P, Bussière T, Weinreb PH, Williams L, Maier M, et al. The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease. Nature. 2016;537(7618):50–6.

Article  CAS  PubMed  Google Scholar 

Bussiere T, Weinreb PH, Dunstan RW, Qian F, Arastu MF, Li M, et al. Differential in vitro and in vivo binding profiles of BIIB037 and other anti-abeta clinical antibody candidates. Neurodegener Dis. 2013. https://misc.karger.com/websites/NDD_2013_011_s_1/AbstractCD/pdf/787.pdf.

Biogen. A randomized, blinded, placebo-controlled single ascending dose study of the safety, tolerability, and pharmacokinetics of biib037 in subjects with mild to moderate Alzheimer’s disease. ClinicalTrials.gov; 2015 Mar [cited 23 Mar 2023]. Report No. NCT01397539. Available at: https://clinicaltrials.gov/ct2/show/NCT01397539.

Ferrero J, Williams L, Stella H, Leitermann K, Mikulskis A, O’Gorman J, et al. First-in-human, double-blind, placebo-controlled, single-dose escalation study of aducanumab (BIIB037) in mild-to-moderate Alzheimer’s disease. Alzheimer’s Dementia. 2016;2(3):169–76.

PubMed Central  Google Scholar 

Biogen. A randomized, double-blinded, placebo-controlled multiple dose study to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of BIIB037 in subjects with prodromal or mild Alzheimer’s disease. ClinicalTrials.gov; 2020 Jul [cited 23 Mar 2023]. Report No. NCT01677572. https://clinicaltrials.gov/ct2/show/NCT01677572.

Biogen. A phase 2, multicenter, randomized, parallel-group, double-blind, controlled study of aducanumab (BIIB037) in subjects with mild cognitive impairment due to Alzheimer’s disease or with mild Alzheimer’s disease dementia to evaluate the safety of continued dosing in subjects with asymptomatic amyloid-related imaging abnormalities. ClinicalTrials.gov; 2021 Aug [cited 30 Mar 2023]. Report No. NCT03639987. https://clinicaltrials.gov/ct2/show/NCT03639987.

Salloway S, Chalkias S, Barkhof F, Burkett P, Barakos J, Purcell D, et al. Amyloid-related imaging abnormalities in 2 phase 3 studies evaluating aducanumab in patients with early Alzheimer disease. JAMA Neurol. 2022;79(1):13–21.

Article  PubMed  Google Scholar 

Biogen. A phase 3 multicenter, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of aducanumab (BIIB037) in subjects with early Alzheimer’s disease. ClinicalTrials.gov; 2021 Aug [cited 30 Mar 2023]. Report No. NCT02477800. https://clinicaltrials.gov/ct2/show/NCT02477800.

Biogen. A phase 3 multicenter, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of aducanumab (BIIB037) in subjects with early Alzheimer’s disease. ClinicalTrials.gov; 2021 Aug [cited 22 Mar 2023]. Report No. NCT02484547. https://clinicaltrials.gov/ct2/show/NCT02484547.

Herring WL, Gould IG, Fillit H, Lindgren P, Forrestal F, Thompson R, et al. Predicted lifetime health outcomes for aducanumab in patients with early Alzheimer’s disease. Neurol Ther. 2021;10(2):919–40.

Article  PubMed  PubMed Central  Google Scholar 

von Rosenstiel P, Haeberlein SB, Castrillo-Viguera C, Chen T, O’Gorman J, Rajagovindan R, et al. Aducanumab 48-month analyses from PRIME, a phase 1b study in patients with early Alzheimer’s disease. 11th Clinical Trials on Alzheimer’s Disease Congress 2018; 2018 [cited 23 Aug 2023]; Barcelona, Spain. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8571451/.

Englund H, Sehlin D, Johansson AS, Nilsson LNG, Gellerfors P, Paulie S, et al. Sensitive ELISA detection of amyloid-β protofibrils in biological samples. J Neurochem. 2007;103(1):334–45.